591 related articles for article (PubMed ID: 34402426)
21. An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility.
Wang L; Balmat TJ; Antonia AL; Constantine FJ; Henao R; Burke TW; Ingham A; McClain MT; Tsalik EL; Ko ER; Ginsburg GS; DeLong MR; Shen X; Woods CW; Hauser ER; Ko DC
Genome Med; 2021 May; 13(1):83. PubMed ID: 34001247
[TBL] [Abstract][Full Text] [Related]
22. Return-to-work, disabilities and occupational health in the age of COVID-19.
Godeau D; Petit A; Richard I; Roquelaure Y; Descatha A
Scand J Work Environ Health; 2021 Jul; 47(5):408-409. PubMed ID: 34003294
[TBL] [Abstract][Full Text] [Related]
23. Association between bisphosphonate use and COVID-19 related outcomes.
Thompson J; Wang Y; Dreischulte T; Barreiro O; Gonzalez RJ; Hanč P; Matysiak C; Neely HR; Rottenkolber M; Haskell T; Endres S; von Andrian UH
Elife; 2023 Aug; 12():. PubMed ID: 37534876
[TBL] [Abstract][Full Text] [Related]
24. Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module.
Lee HK; Knabl L; Knabl L; Wieser M; Mur A; Zabernigg A; Schumacher J; Kapferer S; Kaiser N; Furth PA; Hennighausen L
Sci Rep; 2022 Feb; 12(1):2784. PubMed ID: 35181735
[TBL] [Abstract][Full Text] [Related]
25. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
Ahmad F; Kamal MA; Tekwani BL
Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
[TBL] [Abstract][Full Text] [Related]
26. Sweet Drugs for Bad Bugs: A Glycomimetic Strategy against the DC-SIGN-Mediated Dissemination of SARS-CoV-2.
Cramer J; Lakkaichi A; Aliu B; Jakob RP; Klein S; Cattaneo I; Jiang X; Rabbani S; Schwardt O; Zimmer G; Ciancaglini M; Abreu Mota T; Maier T; Ernst B
J Am Chem Soc; 2021 Oct; 143(42):17465-17478. PubMed ID: 34652144
[TBL] [Abstract][Full Text] [Related]
27. OAS1 gene, Spike protein variants and persistent COVID-19-related anosmia: may the olfactory disfunction be a harbinger of future neurodegenerative disease?
Di Stadio A; Bernitsas E; Ralli M; Severini C; Brenner MJ; Angelini C
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):347-349. PubMed ID: 35113409
[No Abstract] [Full Text] [Related]
28. Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.
Palmos AB; Millischer V; Menon DK; Nicholson TR; Taams LS; Michael B; Sunderland G; Griffiths MJ; ; Hübel C; Breen G
PLoS Genet; 2022 Mar; 18(3):e1010042. PubMed ID: 35239653
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
31. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.
Cantwell AM; Singh H; Platt M; Yu Y; Lin YH; Ikeno Y; Hubbard G; Xiang Y; Gonzalez-Juarbe N; Dube PH
J Virol; 2021 Sep; 95(20):e0101021. PubMed ID: 34319784
[TBL] [Abstract][Full Text] [Related]
32. Host genetic variants associated with COVID-19 reconsidered in a Slovak cohort.
Skerenova M; Cibulka M; Dankova Z; Holubekova V; Kolkova Z; Lucansky V; Dvorska D; Kapinova A; Krivosova M; Petras M; Baranovicova E; Baranova I; Novakova E; Liptak P; Banovcin P; Bobcakova A; Rosolanka R; Janickova M; Stanclova A; Gaspar L; Caprnda M; Prosecky R; Labudova M; Gabbasov Z; Rodrigo L; Kruzliak P; Lasabova Z; Matakova T; Halasova E
Adv Med Sci; 2024 Mar; 69(1):198-207. PubMed ID: 38555007
[TBL] [Abstract][Full Text] [Related]
33. Single nucleotide variants in the
Chávez-Vélez E; Álvarez-Nava F; Torres-Vinueza A; Balarezo-Díaz T; Pilataxi K; Acosta-López C; Peña IZ; Narváez K
Front Cell Infect Microbiol; 2024; 14():1322882. PubMed ID: 38694517
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19.
Dakal TC
Immunobiology; 2021 Jan; 226(1):152021. PubMed ID: 33232865
[TBL] [Abstract][Full Text] [Related]
35. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
Front Immunol; 2022; 13():960733. PubMed ID: 35967323
[TBL] [Abstract][Full Text] [Related]
36. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
37. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.
Glinsky GV
Biomedicines; 2020 May; 8(5):. PubMed ID: 32455629
[TBL] [Abstract][Full Text] [Related]
38. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
39. Proteo-Genomic Analysis of SARS-CoV-2: A Clinical Landscape of Single-Nucleotide Polymorphisms, COVID-19 Proteome, and Host Responses.
Tushir S; Kamanna S; Nath SS; Bhat A; Rose S; Aithal AR; Tatu U
J Proteome Res; 2021 Mar; 20(3):1591-1601. PubMed ID: 33555895
[TBL] [Abstract][Full Text] [Related]
40. The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy.
Preskorn SH
J Psychiatr Pract; 2020 May; 26(3):219-227. PubMed ID: 32421292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
